カテゴリー： China Research and Intelligence, 中国

中国の遺伝子組換え第VIII因子市場2010-2019

【英語タイトル】Investigation Report on China Recombinant Factor Ⅷ Market, 2010-2019

China Research and Intelligenceが出版した調査資料（CRI5062920）・商品コード：CRI5062920
・発行会社（調査会社）：China Research and Intelligence
・発行日：2015年6月11日
・ページ数：30
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：中国
・産業分野：薬剤・医薬品・材料
◆販売価格オプション（消費税別）
Single UserUSD2,000 ⇒換算￥208,000見積依頼/購入/質問フォーム
Enterprisewide（全社内共有可）USD3,000 ⇒換算￥312,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

Description

Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor Ⅷ or Ⅸ, though not rare, which affects mostly males. Hemophilia A (clotting factor Ⅷ deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor Ⅷ while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor Ⅷ (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor Ⅷ too.
After entering China, recombinant factor Ⅷ develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor Ⅷ in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
As hemophiliacs’ ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor Ⅷ in China is expected to keep expanding.

Readers can get at least the following information from this report:
-sales status of recombinant factor Ⅷ in China
-price of recombinant factor Ⅷ in Chinese market
-major manufacturers of recombinant factor Ⅷ in Chinese market
-share of dosage forms of recombinant factor Ⅷ in China
-market outlook of recombinant factor Ⅷ in China

The author suggests the following groups of people purchase this report:
-manufacturers of blood products
-investors/ research institutions interested in China blood products market
-any interest in the Chinese medicine market, please contact CRI for customized survey service

【レポートの目次】

Table of Contents

1 Related Concepts of Recombinant Factor Ⅷ
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Recombinant Factor Ⅷ in China
2.1 Patent and Approval Status of Recombinant Factor Ⅷ in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Recombinant Factor Ⅷ in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Recombinant Factor Ⅷ in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Recombinant Factor Ⅷ in China, 2010-2014
5.1 Market Share of Different Dosage Forms by Sales Value
5.2 Market Share of Different Dosage Forms by Sales Volume

6 Reference Price of Recombinant Factor Ⅷ in Chinese Hospitals in 2014
6.1 Baxter Bioscience Manufacturing (SW) (Trade Name: Advate)
6.2 Wyeth Farma S.A.(SP) (Trade Name: Xyntha)
6.3 Bayer

7 Major Manufacturers of Recombinant Factor Ⅷ in Chinese Market, 2010-2014
7.1 Bayer
7.2 Baxter Bioscience Manufacturing
7.3 Wyeth Farma S.A.

8 Market Outlook of Recombinant Factor Ⅷ in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Patent Status of Recombinant Factor Ⅷ in China
Chart sSales Status of Recombinant Factor Ⅷ in China
Chart Sales Value of Recombinant Factor Ⅷ in China, 2010-2014
Chart Sales Value of Recombinant Factor Ⅷ in Some Regions in China, 2010-2014
Chart Sales Volume of Recombinant Factor Ⅷ in China, 2010-2014
Chart Sales Volume of Recombinant Factor Ⅷ in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Recombinant Factor Ⅷ for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Recombinant Factor Ⅷ Made by Bayer (the US) in China, 2010-2014
Chart Sales Value and Market Share of Recombinant Factor Ⅷ Made by Baxter BioScience(SW) in China, 2010-2014
Chart Sales Value and Market Share of Recombinant Factor Ⅷ Made by Wyeth(SP) in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Recombinant Factor Ⅷ for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of Recombinant Factor Ⅷ Made by Bayer (the US) in China, 2010-2014
Chart Price of Recombinant Factor Ⅷ Made by Baxter Bioscience Manufacturing (SW) in Some Chinese Cities in 2014
Chart Price of Recombinant Factor Ⅷ Made by Wyeth Farma S.A.(SP) in Some Chinese Cities in 2014
Chart Price of Recombinant Factor Ⅷ Made by Bayer (the US) in Some Chinese Cities in 2014



【掲載企業】

Bayer, Baxter Bioscience Manufacturing, Wyeth Farma S.A.

★調査レポート[中国の遺伝子組換え第VIII因子市場2010-2019] (コード：CRI5062920)販売に関する免責事項を必ずご確認ください。
★調査レポート[中国の遺伝子組換え第VIII因子市場2010-2019]についてメールでお問い合わせ

※関連調査レポートはありません。


◆H&Iグローバルリサーチのお客様（例）◆